linjc16/ctgov huggingface dataset:
Primary Obstructive Megaureter Management in Eastern Interregional Area

Study Overview
=================
Brief Summary
-----------------
Congenital obstructive megaureter is a urinary malformation affecting the ureterovesical junction and causing obstruction to the flow of urine. It is the second most common cause of hydronephrosis. This malformation affects four times more boys than girls and is bilateral in 25% of cases. It is also associated with contralateral renal dysplasia in 15% of cases. The obstruction is linked to aperistalsis and hypertrophy of the circular muscle bundles and increased collagen 1 level. This malformation is accessible to antenatal screening from the second trimester. It falls within the scope of CAKUT and requires regular monitoring. Indeed, this uropathy can cause repeated pyelonephritis, kidney scarring and affected kidney function.

Official Title
-----------------
Primary Obstructive Megaureter Management in Eastern Interregional Area : Current Status and Perspectives

Conditions
-----------------
Congenital Obstructive Megaureter

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Minor patient (from 1 to 17 years old) Patient treated between January 2010 and December 2017 in one of the participating centers for an obstructive congenital mega-ureter Subject (and/or his parental authority) not having expressed, after information, his opposition to the reuse of his data for the purposes of this research Exclusion Criteria: Subject (and/or his parental authority) having expressed, after information, his opposition to the reuse of his data for the purposes of this research

Ages Eligible for Study
-----------------
Minimum Age: 1 Year
Maximum Age: 17 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Determine over the past seven years, the operability factors of patients aged 0 to 5 years regardless of the surgical technique used | This study aims to make a retrospective inventory and perspective on the management of congenital obstructive mega ureter | Files analysed retrospectively from January 01, 2010 to December 31, 2017 will be examined | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Congenital obstructive megaureter, Urinary malformation, Ureterovesical junction, Hydronephrosis, Renal dysplasia
Molecular Imaging of Epidermal Growth Factor Receptor in Colorectal Neoplasia Using Confocal Laser Endomicroscopy

Study Overview
=================
Brief Summary
-----------------
The study aims to: Achieve molecular imaging of EGFR in patients with colorectal neoplasia in vivo using confocal laser endomicroscopy. Compare the results of in vivo EGFR-specific molecular imaging with CLE and ex vivo immunohistochemistry .

Detailed Description
-----------------
Various kinds of tumor markers have been shown to be over-expressed in colorectal cancer, including epidermal growth factor receptor(EGFR). The conventional detection method of EGFR expression in colorectal neoplasia is immunohistochemistry which is time-consuming, and the immunoreactivity can be affected by storage and fixation of tissues. Confocal laser endomicrosopy is a newly developed device which could identify the cellular and subcellular structures clearly with the magnification at×1000, making it possible to explore the physiological and pathological molecular mechanism of the gastrointestinal tract. So the study aims to achieve molecular imaging of EGFR in colorectal neoplasia in vivo using confocal laser endomicroscopy.

Official Title
-----------------
In Vivo Molecular Imaging of Epidermal Growth Factor Receptor in Patients With Colorectal Neoplasia Using Confocal Laser Endomicroscopy

Conditions
-----------------
Colorectal Cancer, Colorectal Adenoma

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria： ●Patients known to have large polypoid lesions in colon or rectum from previous examinations from outpatients and inpatients at Qilu Hospital were enrolled into the study Exclusion Criteria: Patients who are allergic to fluorescein sodium Patients with impaired cardiac, liver or renal function Patients who are unwilling to sign or give the informed consent form Patients with giant tumors or obvious GI tract bleeding which make it hard or impossible to observe the lesions Patients with coagulopathy Patients with pregnancy or breastfeeding

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| colorectal cancer<br>Patients with colorectal carcinoma during conventional endoscopic imaging. | |
| colorectal adenoma<br>Patients with colorectal adenoma during conventional endoscopic imaging. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
molecular imaging, epidermal growth factor receptor, colorectal neoplasia, confocal laser endomicroscopy
Cerebral, Meningeal Biopsy by Flexible Endoscopy in Patients Without Neurological Diagnosis

Study Overview
=================
Brief Summary
-----------------
The investigators will take cerebral and subarachnoid biopsy by flexible endoscopy in patients without neurological findings. The investigators will use retrospective and prospective patients.

Detailed Description
-----------------
Test the useful of the flexible endoscopy in patients without neurological diagnosis. Developed a diagnosis method for idiopathic neurological findings. Compare the cerebral and subarachnoid biopsy each other

Official Title
-----------------
Cerebral, Meningeal Biopsy by Flexible Endoscopy in Patients Without Neurological Diagnosis

Conditions
-----------------
Neurological Disease

Intervention / Treatment
-----------------
* Procedure: cerebral flexible endoscopy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients with neurological disease and with out diagnosis Exclusion Criteria: death of the patient patients with neurological diagnosis

Ages Eligible for Study
-----------------
Maximum Age: 85 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| undeterminated neurological disease, cerebral endoscopy<br>patients without neurological diagnosis that require cerebral , meningeal diagnosis | Procedure: cerebral flexible endoscopy<br>* The investigators will make a burrhole in the precoronal suture introducing the flexible endoscope taking a cerebral and a basal meningeal biopsy<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Test the useful of the cerebral and subarachnoid biopsy by flexible endoscopy in patients without neurological findings |  | 2 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Developed a diagnosis method for idiopathic neurological findings. Compare the cerebral and subarachnoid biopsy each other |  | 2 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Cerebral and subarachnoid biopsy, flexible endoscopy, Patients with neurological findings without diagnosis.
Clinical Trial Study About Human Adipose-Derived Stem Cells in the Stroke

Study Overview
=================
Brief Summary
-----------------
The objective of the study is to confirm the safety and possible efficacy of Adipose-Tissue Derived Stem Cells treatment of chronic stroke. Specifically, the study will transplant autologous ADSCs into brain surrounding ischemic infarct in adult (65-80 years old) subjects who have chronic non-hemorrhagic stroke (>6 months).

Detailed Description
-----------------
This open-label clinical trial will compare outcomes of subjects with chronic stroke. Six subjects will be to treatment (n=3) groups. The treatment group will receive brain transplants of autologous ADSCs. Treatment group will receive rehabilitation after the transplantation. Subjects will be assessed by magnetic resonance imaging (MRI) and eight standardized stroke indices: National Institutes of Health Stroke Scale (NIHSS), ( Barthel Index )、 ( Berg balance scale )、 (Fugl - Meyer test )、(Action research arm test )、 (Purdue pegboard )、 ( grip strength measurement ) 、(somatosensory evoked potential, SSEP) at 1 month, 3 months, and 6 months after treatment.

Official Title
-----------------
Adipose-Derived Stem Cells (ADSCs) Injections for Stroke

Conditions
-----------------
Stroke

Intervention / Treatment
-----------------
* Drug: ADSCs


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: stroke investigators with age 65 to 80 years history of stroke between six months and 10 years Systolic pressure and Diastolic pressure were maintained under 160 mmHg and 110 mmHg INR < 2.5, platelets counts 1-5 x 10^5/μl Damaged area range between 0.5 cm to 6 cm by brain MRI Exclusion Criteria: Pregnant women Investigators with AIDS, cancer, liver dysfunction Others can't fit into the trial evaluate by investigator

Ages Eligible for Study
-----------------
Minimum Age: 65 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: GXNPC1<br>Three subjects will be to treatment (n=3) groups. The treatment group will receive brain transplants of autologous ADSCs. Treatment group will receive rehabilitation after the transplantation. Subjects will be assessed by magnetic resonance imaging (MRI) and four standardized stroke indices: National Institutes of Health Stroke Scale (NIHSS), European Stroke Scale (ESS), European Stroke Motor Subscale (EMS), Barthel Index, MMSE and Gait analyses at 1 month, 3 months, and 6 months after treatment. | Drug: ADSCs<br>* Autologous ADSCs<br>* Other names: hADSCs;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Neurological function | Blood biochemical, Neurobehavioral examination (NIH Stroke Scale 16-20) | 6 months |
In-Patient Study In Schizophrenic Patients

Study Overview
=================
Brief Summary
-----------------
This study is a placebo-controlled study to assess the safety and tolerability of a novel antipsychotic medication, (773812) when given to schizophrenic patients for twenty-eight days. Assessments include blood sampling to determine drug concentrations, psychiatric assessments while under treatment, and movement assessments to evaluate potential side effects.

Official Title
-----------------
A Placebo Controlled, Double-Blind, Randomised Study Investigating the Safety, Tolerability and Pharmacokinetics of Ascending Multiple Oral Doses of SB-773812 in Male and Female Schizophrenic Patients for up to 28 Days

Conditions
-----------------
Schizophrenia

Intervention / Treatment
-----------------
* Drug: SB773812


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Must have schizophrenia that has been stable for at least three months. Willing to discontinue current anti-psychotic medications (under supervision) prior to the study. Willing to live at the study center for a total of 38 days and then return for three follow-up visits. Exclusion Criteria: Taking medications for conditions other than schizophrenia. History of alcohol or drug abuse within six months of the study, and their alcohol consumption must meet moderate guidelines.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 55 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: SB773812|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Safety and Tolerability of 773812 during 28 days of dosing. Pharmacokinetics of 773812 after repeat dosing. |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Assessment of (1) changes in testing scores on a range of psychiatric assessments (PANSS, BPRS. CGI) (2) psychometric performance and (3)body weight/ girth measurement /glucose and lipd measurement, each as a function of duration of dosing. |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Schizophrenia, safety, tolerability, pharmacokinetics
Bone Accrual and Hormones in Response to Lactation

Study Overview
=================
Brief Summary
-----------------
This is a prospective observational trial of healthy postpartum women to investigate changes in bone density and markers of bone turnover during lactation. The study hypothesis is that women who breast-feed 5 months or more will lose bone density and subsequently regain the bone density after weaning. This study seeks to define determinants of the regain in bone density.

Detailed Description
-----------------
This is a prospective observational trial enrolling healthy postpartum women, ages 20 years and older with the intent to breast-feed from the UNC outpatient obstetrical clinics and the UVA outpatient obstetrical clinics. These women were studied at 3-5 visits in the year following their delivery to assess bone density, nutritional intake, exercise, and breast-feeding choices. The number of study visits depended on the timing of return of menses and interest in participating in the follow-up study (timepoints are: immediate postpartum, 3 months postpartum, return of menses, 6 months after return of menses and follow-up visit 6 months after final visit). Blood was taken for analysis of bone-related hormones, bone turnover and calcium homeostasis markers. The study focuses on women with extended lactation (at least 5 months of lactation) whereas women who cease lactation prior to 3 months will be the primary comparison group.

Official Title
-----------------
Bone Accrual and Hormones in Response to Lactation

Conditions
-----------------
Lactation

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: age >20 at the time of delivery singleton pregnancy and <2 prior pregnancies that were >20 weeks gestation. Exclusion criteria: maternal rheumatologic disorders maternal anorexia nervosa maternal endocrinologic disorders, medications known to affect bone density such as corticosteroids, thyroid hormone use, anticonvulsant therapy, bisphosphonates, long-term GnRH agonists use and calcitonin. Subsequent pregnancy during the study

Ages Eligible for Study
-----------------
Minimum Age: 20 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The association of change in bone density and change in IGF-1 axis hormones during lactation and weaning |  |  Two Years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The association of changes in bone density and change in bone turnover markers during lactation and weaning. |  |  Two years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Bone Density, Lactation, Bone Turnover Markers
Prophylaxis of Venous Thrombo-Embolism in Cancer Patients Under Palliative Care

Study Overview
=================
Brief Summary
-----------------
To determine the efficacy and to measure the complications of prophylactic anticoagulation using low-molecular weight heparin in adult cancer patients under palliative care

Conditions
-----------------
Cancer, Venous Thromboembolism

Intervention / Treatment
-----------------
* Drug: nadroparin


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Cancer patients in palliative care Patients fully informed about their condition Signed informed consent No exclusion criteria Exclusion Criteria: Absence of advanced cancer Cancer previously cured Venous thromboembolism diagnosed within 6 months prior to inclusion Absence of discerning capacity Active anti-thrombotic treatment with heparins or coumarines Thrombocytopenia <50G/l PTT >45sec TP<35% Active bleeding Renal failure <20ml/min Past history of heparin-induced thrombocytopenia

Ages Eligible for Study
-----------------
Minimum Age: 0 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: nadroparin|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Evaluation of the Optimum Brushing Force on Dental Plaque Removal and the Abrasive Effect of Brushing Force on Enamel Surface.

Study Overview
=================
Brief Summary
-----------------
Objective To determine the optimum brushing force for dental plaque removal. To investigate the effect of brushing force on enamel characteristic. Hypothesis H0 : Structural tooth loss is not significantly different between before and after brushing with excessive force on enamel surface. H1 : Structural tooth loss is significantly different between before and after brushing with excessive force on enamel surface. Study design: Experimental study

Official Title
-----------------
Evaluation of the Optimum Brushing Force on Dental Plaque Removal and the Abrasive Effect of Brushing Force on Enamel Surface: An in Vitro Study.

Conditions
-----------------
the Optimum Brushing Force for Dental Plaque Removal and the Effect of Brushing Force on Enamel Characteristic

Intervention / Treatment
-----------------
* Procedure: brushing force


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: extracted bovine incisors Exclusion Criteria: no
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: brushing force<br> | Procedure: brushing force<br>* Using duplication method, vertical force was applied from 1-5.5 N in linear mesial-distal brushing motion at 4 strokes per second for 5 seconds Force was increase 0.5 N in every testing until plaque was completely removed from enamel surface<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| optimum force | The toothbrush holder was adjusted allowing toothbrush bristle to press onto the tooth surface until the loading monitor indicated the designated vertical loading force. Loading force was applied from a minimum of 1 N, with an increment of 1 N to a maximum of 6 N. The optimum force which remove all dental plaque from tooth surface will recorded. | 5 seconds |
Effect of Radiation Therapy Among Head and Neck Cancer Patients on the Inner Ear Function

Study Overview
=================
Brief Summary
-----------------
Aims: 1. To evaluate the effects of radiation therapy on the inner ear, among patients treated with radiation therapy for head and neck cancers using a wide battery of tests (Audiometry and tympanometry, vHIT, VEMP, ENG) ; 2. To correlate the mean total radiation dose to the cochlea with the effects on audiological and vestibular function

Official Title
-----------------
Evaluation of the Effect of Radiation Therapy Among Head and Neck Cancer Patients on the Inner Ear Function Using Novel Techniques

Conditions
-----------------
Head and Neck Cancer Patients Treated With Radiotherapy

Intervention / Treatment
-----------------
* Diagnostic Test: Audiometry and tympanometry, vHIT, VEMP, ENG


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Females and males, Age: ≥ 18 years old Patients diagnosed Head and Neck cancers, not treated previously Planned for radiation therapy in which the inner ear will be radiated Exclusion Criteria: Patients who were previously diagnosed with a vestibular disorder Previous middle or inner ear anomaly Failure to complete the whole course of radiation therapy More than one course of radiation therapy Patients treated with concurrent ototoxic chemotherapy Pregnant women Patients who will not sign an informed consent form Helpless or incompetent patients

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Head and Neck Cancer patients<br> | Diagnostic Test: Audiometry and tympanometry, vHIT, VEMP, ENG<br>* Diagnostic tests<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Audiometry | The change in hearing threshold and in the speech-audiometry | 1.5 Year | 
| ENG test | Abnormal function of the central vestibular pathways, unilateral weakness of the vestibular apparatus or direction preponderance | 1.5 Year | 
| VEMP test | Abnormal latencies, amplitudes, thresholds | 1.5 Year | 
| vHIT test | abnormal gain, the appearance of overt and covert saccades | 1.5 Year |